Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Ebix, Inc.
April 10, 2021 09:09 ET
|
Kessler Topaz Meltzer & Check LLP
RADNOR, Pa., April 10, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States...
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages CytoDyn Inc. Investors to Secure Counsel Before Important May 17 Deadline – CYDY
April 10, 2021 09:00 ET
|
The Rosen Law Firm PA
NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTC: CYDY) between March 27, 2020 and March...
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting
April 10, 2021 09:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
New Clinical Responses for AGEN1181 Presented at AACR
April 10, 2021 08:35 ET
|
Agenus Inc.
7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen in patients typically unresponsive to I-O agents ...
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
April 10, 2021 08:31 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
April 10, 2021 08:31 ET
|
Advaxis, Inc.
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade Assay enables determination of PD-1...
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
April 10, 2021 08:31 ET
|
Jounce Therapeutics, Inc.
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature- - JTX-8064’s mechanism of...
Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
April 10, 2021 08:31 ET
|
Vincerx Pharma, Inc.
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies on track for 1H 2022 PALO ALTO, Calif., April 10, 2021 (GLOBE NEWSWIRE)...
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
April 10, 2021 08:31 ET
|
Hookipa Pharma Inc
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202Early data on HB-201 monotherapy show an...
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
April 10, 2021 08:31 ET
|
Arch Oncology
BRISBANE, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today...
- May 10, 2024 04:10 ET Global Wireless Broadband in Public Safety Analysis Report 2024: Market to Surpass $155 Billion by 2032, Driven by Escalating Demand for Secure and Dependable Wireless Communication Systems
- May 10, 2024 04:02 ET Rail Composites Market Set to Surge with a 7.2% CAGR Through 2028, Driven by Technological Advancements in Manufacturing